Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entire-body PET Scans for Multiple Sclerosis
NCT04390009Phase 1Recruiting
- Sponsor
- Brain Health Alliance
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of Florbetapir in multiple sclerosis (MS) (2 arms), sponsored by Brain Health Alliance. Primary endpoints: Entire-body PET imaging of demyelination of peripheral and central nervous system at 1 day and Psychometric questionnaire for monitoring psychological health at 90 days. Started Sep 2024; status: recruiting.
02
Drugs
Florbetapir
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04390009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390009.